Latest News
Conference Coverage
Study highlights need to investigate psoriasis treatment outcomes in skin of color patients
MIAMI – Researchers used phase 2 and 3 psoriasis clinical trial data to explore potential differences in treatment response in various ethnic...
News
Xeljanz: FDA panel recommends ulcerative colitis indication
SILVER SPRING, MD. – Federal advisors to the FDA on March 8 voted unanimously to recommend approval of tofacitinib (Xeljanz) for ulcerative...
Conference Coverage
Phase 3 trials show halobetasol/tazarotene lotion works for psoriasis
KAUAI, HAWAII – “Tazarotene: Great for acne, but think of it again for psoriasis.”
Conference Coverage
Online psoriasis consultations shown equivalent to office visits
SAN DIEGO – Patients with psoriasis managed for 1 year by physician telemonitoring had equivalent outcomes, compared with patients managed in...
Conference Coverage
VIDEO: PPACMAN aims to advance the combined rheum-derm clinic approach in the community
SAN DIEGO - The idea behind starting PPACMAN the Psoriasis and Psoriatic Arthritis Clinics Multicenter Advancement Networkwas to form clinics at...
Conference Coverage
Could guselkumab be a disease-modifying agent in plaque psoriasis?
SAN DIEGO – Questions remain about why some patients maintain durable response.
Conference Coverage
Ustekinumab quells aortic inflammation in patients with severe psoriasis
SAN DIEGO – The benefit may be a class-associated effect.
Conference Coverage
VIDEO: With new therapies available, it’s the ‘decade of eczema,’ researcher says
SAN DIEGO – “This revolution in atopic dermatitis, or eczema, stems from our increased knowledge of the disease.”
News
Biologics have best chance of achieving PASI 90 in psoriasis
Results derived from a meta-analysis of 109 randomized, controlled trials contrast with real-world treatment recommendations.